Purpose In modelling studies using pharmacists' opinions, drug-related morbidity (DRM) and preventable DRM have been more common than in observational studies, and the resulting costs are extensive. Modelling studies' estimates may vary depending on informants' profession. The purpose of this modelling study was to estimate the proportion of patients with DRM and preventable DRM and the cost of illness (COI) of DRM in Sweden based on physicians' expert opinions. Method A conceptual model of DRM was modified from previous studies. Using a modified Delphi technique, a panel of physicians (n019) estimated the probabilities of DRM, preventable DRM, and clinical outcomes of DRM separately for outpatients and inpatients. DRM included new medical problems (adverse drug reactions, drug dependence, and intoxications by overdose) and therapeutic failure (insufficient effects of medicines, and morbidity due to untreated indication). A COI analysis included the direct costs of DRM. Results Physicians estimated that 51±22% [mean ± standard deviation (SD)] of outpatients experience DRM and 12±8% preventable DRM. Of inpatients, 54±17% was estimated to experience DRM and 16±7% preventable DRM. Of outpatients with DRM, 24±11% was estimated to experience preventable DRM, whereas this proportion for inpatients was 31±15%. The estimated COI was 376 euros per outpatient and 838 euros per inpatient. Conclusions Swedish physicians estimated that every other outpatient and inpatient experiences DRM, which is often preventable and costly. As physicians' estimates on the proportion of patients with DRM were higher than in observational studies in restricted subpopulations, DRM may be more common in the general population than observational studies suggest.
Introduction
A significant proportion of patients is reported to suffer from drug-related morbidity (DRM), such as adverse drug reactions (ADRs) and therapeutic failure [1, 2] , but evidence from observational and modelling studies are partially inconsistent. In a US modelling study using probability estimates of an expert panel of pharmacists in the 1995, 40% of ambulatory patients receiving medication was estimated to experience DRM [3] . According to Swedish pharmacists' recent estimation, 61% of all patients using healthcare experience DRM [4] . These estimates on the proportion of patients with DRM are higher than in most observational studies, in which the median frequency of adverse drug events (ADEs) among inpatients is reported to be 6% [2] , and 5% of hospital admission is estimated to be drug related, with a range from 0.01% to 54% in individual studies [1] . In modelling studies with an expert pharmacist panel, pharmacists' perception on DRM may be subjective, and estimates on DRM could differ if other health professionals were used as experts, as suggested by a modelling study in nursing homes [5] .
In modelling studies with a pharmacist panel, the costs to healthcare due to DRM are extensive: in Sweden 6,600 million euros among all patients in 2010 [4] and in the United States US $89,000 million among ambulatory patients in 1995 [3] and US $117,000 million in 2001 [6] . However, patient-level costs were 1,645 euro per patient with DRM in the Swedish modelling study [4] , which is lower than in most observational studies [7] . As modelling study cost estimates are based on pharmacists' perceptions on the clinical outcomes of DRM, in addition to their high estimates on the proportion of patients with DRM, the costs of DRM may also differ if a panel of other health professionals was used in modelling studies.
For preventing unnecessary patient harm and costs for healthcare, the preventability of DRM is particularly interesting. The Swedish modelling study's estimate that 45% of all patients with DRM suffer from preventable DRM [4] was similar to or slightly higher than in observational studies [2, [8] [9] [10] [11] [12] [13] . However, the Swedish modelling study's conclusion [4] that 27% of all patients experienced preventable DRM was significantly higher than in observational studies [10, 11, 13] .
Modelling studies using experts' opinion for probabilities of DRM and related outcomes may provide valuable evidence on DRM at a population level, as observational studies are limited to specific subpopulations, such as patients in certain care units. However, the results of previous modelling studies using pharmacists' probability estimates, based on their subjective view and experience in clinical practice, are partially inconsistent with other evidence. Thus, other health professionals' estimates should be used in modelling studies to investigate whether results vary. The purpose of this modelling study was to estimate the proportion of patients with DRM and preventable DRM and to estimate the cost of illness (COI) of DRM in Sweden based on physicians' expert opinions.
Methods
A conceptual model on DRM with a decision tree was modified from a previous US study [3] . The model was modified for the Swedish health system and for an expert panel of physicians (Fig. 1) . The panel estimated probabilities of DRM and related outcomes in the decision tree using modified Delphi methodology with two rounds [14] . Physicians working in outpatient care (n011) provided estimates for outpatients, and physicians working with inpatients (n0 8) for inpatients. However, DRM among inpatients could also originate from outpatient settings. To gain approximately 20 panelists representing both outpatient and inpatient care and different specialties, a strategically stratified sample of 20 physicians active on drug and therapeutics committees was invited to participate in the study. Six strata represented specialties or combinations of specialties, and the desired number of participants in each stratum was chosen in proportion of patient consultations in each stratum. The invited physicians were also chosen to represent rural and urban as well as academic and nonacademic healthcare. When an invited physician in a stratum declined participation, another physician in the stratum was invited based on a predefined list of potential participants representing different specialties. From a total of 53 invited specialist physicians, 19 representing the six strata consented, forming the expert panel. Five specialized in general medicine, four in internal medicine, and three in geriatrics. Each of the remaining seven was specialized either in psychiatry, dermatology, rheumatology, urology, infectious diseases, general surgery, or pediatrics. Six physicians practiced in university hospitals and eight in general hospitals. Eight physicians based in a hospital practiced primarily with inpatients and six with outpatients. Five physicians practiced in primary care in district healthcare centers. Twelve physicians were men and seven were women, with a mean age of 57 (range 45-69) years.
In Section A of the decision tree, physicians estimated the probabilities of drug therapy outcomes among their patients (Fig. 1) . New medical problems (NMPs), therapeutic failure (TF) and a combination of NMPs and TF as outcomes represented DRM. DRM could originate from prescribed drugs, nonprescription drugs, or complementary medicines; morbidity related to drugs without approval for medical purposes was excluded. NMPs included ADRs, drug dependence, and intoxications by overdose. TF included insufficient effects of medicines due to erroneous therapy, including morbidity due to lack of drug therapy despite indication, or when rational use of medicines was insufficient. In Section B, physicians estimated the proportion of patients with preventable DRM according to established criteria, including DRM that was "due to a drug treatment procedure inconsistent with present day knowledge of good medical practice or was clearly unrealistic, taking the known circumstances into account," or DRM when "the prescription was not erroneous, but the drug event could have been avoided by an effort exceeding the obligatory demands" [15] . Clinical outcomes of DRM are estimated in Section C. In Sections A and C, the response alternatives were mutually exclusive. In Section C, respondents were instructed to choose the worst response alternative when multiple clinical outcomes due to DRM were present. The conceptual model was the same for outpatients and inpatients apart from one response alternative in Section C (Fig. 1) , where the probability of a hospitalization was estimated for outpatients and the probability of prolonged hospital stay for inpatients. The Swedish conceptual model was piloted with six pharmacists, six physicians, and four nurses, representing both outpatient and inpatient care. Based on the pilots, the arms of the decision tree were adapted for a panel of outpatient and inpatient physicians (Fig. 1) , and the face and content validity of the final model was assessed.
In the first round, at least one researcher (DA, HG, or KH) instructed the physicians face to face in interpreting the decision tree. The physicians provided their estimates independently, in writing, and were encouraged to leave written comments. Additional information was collected on participants' age, sex, and workplace. Participants also completed an appraisal of the decision tree in which they estimated in a five-point Likert scale how easy each section of the decision tree was to answer. In the second round, conducted through mail, participants could adjust their estimates after receiving interquartile ranges of the entire panel's estimates and a copy of their own estimates from the first round. The appraisal of the decision tree could also be revised. As one physician made no revisions in Section A, four in Section B, one in Section C, and five in the appraisal, answers from the first round were used for these questions. Answers were returned in a prepaid envelope.
Analyses
Proportion of patients with DRM and preventable DRM The estimates were analyzed separately for outpatients and inpatients. The proportion of patients with DRM was Fig. 1 Layout and response alternatives in the conceptual model on drug-related morbidity. 1 Physicians working in outpatient care (n011) provided estimates for outpatients. 2 Physicians working with inpatients (n08) provided estimates for inpatients. 3 Patients with a new medical problem, therapeutic failure, or their combinations represent patients with drug-related morbidity calculated using mean probabilities for patients experiencing NMPs and TF. The proportion of preventable DRM (NMPs or TF) among patients with DRM was calculated by taking respondents' mean estimates. The total proportion of patients with preventable DRM among patients with DRM was calculated by weighting, for each respondent, the proportion of patients with preventable NMPs and TF (among patients with NMPs and TF) by the mean proportion of NMP and TF patients among all DRM patients (i.e., patients with any NMPs or TF). The weighted estimates were summed for each respondent and a mean was taken. The proportion of patients with preventable NMPs and TF among all patients was calculated by weighting, for each respondent, the proportion of patients with preventable NMPs and TF (among patients with DRM) by the estimated probabilities of NMPs and TF among all patients. The mean of the sum of these estimates represented the total proportion of patients with preventable DRM. Even though response distributions were not apparent due to the small sample size, distributions were reasonably symmetrical. Therefore, and because means and medians did not differ notably, the use of means was considered appropriate. Calculations were done using STATA version 10.0.
Cost of illness analyses
The COI analysis was conducted separately for DRM among outpatients and inpatients, folding back in the decision tree (TreeAge Pro Excel 2009). First, conditional probabilities for clinical outcomes were calculated by multiplying mean probabilities for each type of DRM with mean probabilities for clinical outcomes of each type of DRM. Second, each conditional probability was multiplied by its pathway costs (Table 1) , resulting in cost estimates for each clinical outcome. The sum of these clinical outcome costs represented the total COI of DRM per outpatient and inpatient. The annual COI of DRM among outpatients and inpatients was calculated under the assumption that 70% of residents in Sweden visit outpatient care and 9.5% of residents are hospitalized at least once annually [16, 17] .
The pathway costs used in the main analyses and the minimum and maximum pathway costs for each clinical outcome were determined from their cost-generating components ( Table 1 ). The minimum pathway costs represented the most conservative cost estimate and the maximum pathway costs a reasonable worst-case scenario. The costgenerating components were decided upon based on published literature [8, [18] [19] [20] [21] and the researchers' conservative estimates. Monetary values for the components were determined from national statistics [22] [23] [24] and personal communications with register holders (H. Gyllensten. Personal communication) on costs of healthcare and drug use. The cost-generating components and pathway costs were the same for outpatients and inpatients apart from: (a) no additional treatment, (b) additional treatment, and (c) specialist referral. For outpatients, the costs of these clinical outcomes included an initial contact to primary care, whereas contact to primary care was omitted from costs for inpatients. Swedish cost data were converted to euros using the 2010 exchange rate [25] .
Sensitivity analyses of cost of illness
To investigate the robustness of the COI analysis, the probabilities of DRM and its clinical outcomes were varied from the first to the third quartile of the participants' estimates. In another sensitivity analysis, clinical outcomes with most insecurity in the COI analysis were investigated through Tornado diagrams, in which the determined costgenerating components and pathway costs for each clinical outcome are varied from minimum to maximum costs (TreeAge Pro Excel 2009).
Results

Proportion of patients with DRM and preventable DRM
Physicians estimated that 51±22% [mean ± standard deviation (SD)] of all outpatients and 54±17% of all inpatients experience DRM (Table 2 ). Among outpatients with DRM, 24±11% was estimated to experience preventable DRM. Among inpatients with DRM, DRM was considered preventable for 31±15%; 12±8% of all outpatients and 16±7% of all inpatients were estimated to experience preventable DRM. The proportions of patients with all and preventable NMPs, TF, and their combinations are presented in Table 2 .
Cost of illness of DRM
Physicians estimated that 26% of outpatients with NMPs, 14% with TF, and 8% with the combination of both require no addition treatment due to DRM (Table 3) . Of inpatients, 27% with NMPs, 7% with TF, and 7% with combination was estimated to require no additional treatment. For the remaining proportions of outpatients and inpatients with DRM, the DRM was estimated to result in additional treatment, specialist referral, prolonged hospital stay, hospitalization, advanced specialist care, or death. Based on the probability estimates for these clinical outcomes, the COI was 376 euros per outpatient and 838 euros per inpatient (Table 4) . Of the COI per outpatient, hospitalizations and advanced specialist care due to DRM caused 75% (283 euros) of the costs. Prolonged hospital stay and advanced specialist care due to DRM caused 81% (678 euros) of the costs among inpatients. The COI of DRM per outpatient and euros among outpatients experiencing both NMPs and TF and 3,252 euros among inpatients experiencing both NMPs and TF. Extrapolated to the Swedish population, the total annual COI of DRM was 2,500 million euros for outpatients and 800 million euros for inpatients.
Sensitivity analyses of cost of illness
The COI of DRM per outpatient ranged from 97 euros for the first quartile to 447 euros for the third quartile probability estimates. The range was 209-1,177 euros for inpatients.
Of the clinical outcomes of DRM among outpatients, the costs differed the most for hospitalization (cost range 63-257 euros) when the first and third quartile probability estimates were used. Among inpatients, the cost difference was the largest for advanced specialist care (cost range 87-677 euros). According to the Tornado diagrams, the COI among outpatients was the most sensitive to changes in costs resulting from hospitalizations, with cost estimates of 330 euros per outpatient using minimum and 445 euros using maximum pathway costs (Figs. 2 and 3 ). The COI among inpatients was the most sensitive to costs resulting from prolonged hospital stay (cost range 747-1,480 euros).
Discussion
In our modelling study, Swedish physicians perceived that approximately half of their patients experience DRM. The estimates were almost equal for outpatients and inpatients. Our estimates were lower than Swedish pharmacists' estimation that 61% of all patients attending health care experience DRM [4] , but higher than US pharmacists' estimate in 1995 that 40% of outpatients who receive medicines suffer from DRM [3] . Comparing the Swedish studies, pharmacists working clinically may have estimated the proportion of DRM higher if they encounter patients with DRM in their clinical practice rather than average patients. Alternatively, pharmacists working in the community may encounter persons with DRM who do not visit outpatient physicians. Pharmacists may also provide high DRM estimates, perhaps unconsciously, to justify their professional role. Physicians may have given lower estimates because they were asked to provide estimates from their own experience and may have perceived that acknowledging DRM would reflect poorly on their own practice. Nonetheless, the modelling studies combined suggest that up to 40-60% of all patients may experience DRM, even though results from modelling studies must be compared and interpreted with caution. In our and previous modelling studies using health professionals' expert opinion [3, 4] , the proportion of patients The same as by folding back of the decision tree, the total COI may not total the sum of the costs of clinical outcomes because of rounding Fig. 2 Tornado diagram sensitivity analysis for the cost of illness (COI) of drug-related morbidity (DRM) among outpatients. The expected value in is the resulting costs from varying the pathway costs of each clinical outcome from minimum (min) to maximum (max) costs in euros with DRM is significantly higher than in reviews of observational studies [1, 2] , in which approximately 5-6% of patients attending hospitals is estimated to experience DRM. As observational studies among outpatients commonly investigate drug-related hospital admissions, estimates based on experts' opinions may be higher because they include DRM in primary care that does not lead to hospitalizations. For both inpatients and outpatients, part of DRM may be overseen in observational studies because different data sources, such as self-reports and medical records, detect different types of DRM and none of them alone detects all DRM [26] . In addition, modelling studies' estimates may be higher due to a broader definition for DRM. TF is often unspecified in observational studies, potentially leading to being overlooked. When patients with TF exclusively are excluded from our results, physicians' estimates were 36% of outpatients and 34% of inpatients, still significantly higher than in observational studies. Finally, estimates on DRM in modelling studies using an expert panel may be high, because informants were active on drug and therapeutics committees and thus had an interest in drug safety. However, as physicians' estimates on DRM were also higher than in observational studies, high estimates based on pharmacists' expert opinion are not entirely explained by pharmacists' subjective view. Thus, DRM in the entire healthcare may be more common than observational studies suggest. Based on Swedish physicians' estimates, the direct costs of DRM were 376 euros per outpatient and 838 euros per inpatient attending healthcare. Although differing methods for modelling DRM in different health systems hinders the direct comparison of the resulting costs, our estimate for outpatients is similar to US pharmacists' estimates that in the United States, DRM cost US $194 per physician outpatient visit in 1995 [3] , and US $376 in 2001 [6] . Our cost estimate for outpatients is also similar to cost estimates in Germany, where DRM was estimated to cost 434 euros per outpatient visit, combining US probability estimates and German data on clinical outcomes [27] . However, Swedish pharmacists estimated DRM to cost markedly more: 997 euros per patient attending healthcare [4] . The difference between Swedish pharmacists' and physicians' cost estimations is partially attributable to physicians' lower estimates for the proportion of patients with DRM. Moreover, the pharmacists' estimates were based on all patients attending healthcare, whereas physicians responded based on patients either in outpatient or inpatient settings. Thus, physicians' estimates did not represent DRM in all patients attending healthcare. For outpatients, the difference is largely explained by physicians' more conservative probability estimates for the most severe and expensive clinical outcomes. According to physicians, DRM leads to a hospitalization among 5% of outpatients with DRM, to advanced specialist care among 0-2%, and to death among 0%. According to pharmacists, DRM causes a hospitalization to 9-15% of all patients with DRM, advanced specialist care to 2-4%, and death to 1-4% [4] . As for the probability of DRM, the estimate differences may arise from different professional roles. Due to physicians' lower cost estimates per patient, the extrapolated annual costs of the DRM for Swedish healthcare, 2,500 million euros for outpatients and 800 million euros for inpatients, are also lower than estimated by pharmacists [4] : 6,600 million euros in total for all patients. Even though physicians' costs estimates were lower than pharmacists', the annual costs of DRM for the Swedish healthcare system were also substantial according to physicians.
Compared with observational study results [7] , our cost estimates per patient with DRM are low, as in other modelling studies [4, 27] . In observational studies, the cost of DRM has been US $422-7,062 per outpatient with DRM and US $2,284-5,640 per inpatient with DRM (2000 values) [7] . Based on physicians' estimates in our study, DRM costs 730 euros per outpatient with DRM and 1,542 euros per inpatient with DRM, whereas Swedish pharmacists estimated that DRM costs 1,645 euros per patient with DRM [4] . In Germany, the average cost per outpatient with DRM was 381 euros [27] . For both outpatients and inpatients, observational studies' average per patient costs were probably higher because they commonly focus on costs of emergency visits, hospitalizations, and prolonged hospital stay. In the modelling studies, costs included also relatively inexpensive clinical outcomes, such as no additional treatment and additional treatment, which decreases the average costs.
Swedish physicians' estimates on the proportion of patients with preventable DRM were lower than estimates by pharmacists [4, 28] . Among patients with DRM, 24% of outpatients and 31% of inpatients were perceived by physicians to experience preventable DRM, whereas Swedish Fig. 3 Tornado diagram sensitivity analysis for the cost of illness (COI) of drug-related morbidity (DRM) among inpatients. The expected value in is the resulting costs from varying the pathway costs of each clinical outcome from minimum (min) to maximum (max) costs in euros pharmacists estimated that among patients with DRM, 45% suffer from preventable DRM [4] . Although the proportion of preventable DRM was not assessed in the US modelling study, US pharmacists estimated that 53-60% of NMPs and TF could be avoided if ambulatory patients received pharmaceutical care [28] . Pharmacists' avoidability estimates were higher than physicians' also in another US modelling study on DRM in nursing homes [5] , in which pharmacists estimated that 48% and physicians that 34% of DRM is avoided through pharmaceutical care, although no statistical significance between the professionals' estimates was observed. In literature reviews of observational studies, the median or pooled preventability of drug-related admissions, ADEs, or ADRs is between 21% and 59%, with a range of 11-90% in individual studies [2, [8] [9] [10] [11] [12] [13] . Pharmacists' preventability estimates were slightly higher and physicians' slightly lower than in most observational studies. The reasons for pharmacists' high and physicians' low estimates may be the same as for the occurrence of DRM. Preventability was also defined through the presence of substandard care in our study [15] , which may have discouraged physicians to acknowledge preventability. As methods for assessing the preventability of DRM are limited and diverse [29, 30] , the preventability of DRM and the proportion of patients with preventable DRM remains unknown but appears to range between 20% and 60%.
Swedish physicians' estimates that 12% of all outpatients and 16% of all inpatients experience preventable DRM were lower than Swedish pharmacists' estimate: 27% for all patients [4] . As discussed before, the difference is partially attributable to physicians' lower estimates for the proportion of patients with DRM but mainly to physicians' lower preventability estimates. However, both expert panels' estimates are markedly higher than in observational studies, in which the median or pooled proportions of patients with preventable DRM are between 2% and 4% [10, 11, 13] . This difference originates from the expert panels' higher estimates on the proportion of all patients with DRM, whereas preventability estimates were similar. As for the proportion of patients with all DRM, these results suggest that preventable DRM in the entire healthcare may also be more common than observational studies have reported.
Several limitations arise from using a decision tree. The decision tree was a simplified model of DRM and thus does not represent all scenarios for and outcomes of DRM. In our pilot study, informants perceived long-term consequences of DRM, such as residential care, impossible to estimate. We therefore excluded long-term consequences from the decision tree, which may have lead to underestimating the costs of DRM. As decision trees lack a time window [31] , we were unable to determine the prevalence of DRM in a given time, which limits the extrapolation of our results. Informants may also have considered lifetime prevalence, resulting in high estimates for patients experiencing DRM. However, we believe this is unlikely, because the physicians were asked the proportion of patients that have various outcomes, opposite to have had, which would refer to lifetime prevalence. In addition, we instructed our panelists to provide estimates based on their current experience.
As an expert panel and a modified Delphi technique were used for gaining probabilities in the decision tree, our estimates represent the physician panelists' perception and have to be interpreted with caution. Even though using empirical probability estimates in modelling studies is recommended, the Delphi technique is appropriate when no empirical data is available [32] , which was the case for the proportion of patients with DRM and preventable DRM and the clinical outcomes of DRM in the entire healthcare setting. Traditionally in the Delphi methodology, multiple rounds are performed until a consensus within the panel is reached. We decided in advance to conduct two rounds. Although mean estimates did not differ between rounds, SDs narrowed slightly after the second round, though they were still large. A better consensus may have been reached if further rounds had been performed. Further, panel composition, which included physicians' medical specialties, practice settings, and previous experience, may have influenced results.
As definitions for DRM and criteria for preventability are diverse [30, 33, 34] , our estimates may not be comparable with studies using other definitions and criteria. Unlike in the US modelling study [3] , DRM in our study could originate from nonprescribed drugs or complementary medicines, and TF could be caused by lack of drug therapy despite indication. Thus, we included DRM among all patients attending outpatient or inpatient care rather than the number of visits resulting in prescribed drugs. Our informants may also have interpreted the definitions differently, causing variation in their estimates. To facilitate an accurate interpretation of the decision tree and the definitions, we purposefully selected physicians active on drug and therapeutics committees. Further, we explained the decision tree and the definitions to each physician face to face before they provided probability estimates. Despite our efforts to facilitate the interpretation of the model, nine (47%) physicians perceived Section A, 12 (63%) Section B, and 13 (68%) Section C of the decision tree as somewhat difficult or difficult (score 4 or 5 in a five-point Likert scale) to answer after the second round, which must be considered when their mean estimates are interpreted.
The COI of DRM was sensitive to changes in physicians' probability estimates for the proportion of patients with DRM and clinical outcomes of DRM, with almost fivefold cost increase from the most to the least conservative probabilities. In addition, the COI analysis was sensitive to changes in the predetermined pathway costs for clinical outcomes, with variations in pathway costs of hospitalization and prolonged hospital stay influencing the COI analyses the most. Thus, the COI of DRM among outpatients and inpatients in our study are approximates and need to be verified in empirical studies. As indirect costs were excluded, our cost estimations may be underestimations of the economic burden of DRM to the society.
Conclusions
Swedish physicians estimated that every other outpatient and inpatient experiences DRM, which is often preventable and costly. These estimates were lower than Swedish pharmacists' estimates, indicating that informants' profession influences the results in modelling studies using experts' estimates. Physicians' estimates on the proportion of patients with DRM in the entire healthcare system were still higher than in observational studies in restricted subpopulations. Thus, both nonpreventable and preventable DRM may be more common in the general population than evidence suggests. To examine the findings of modelling studies, future empirical research should investigate DRM and its characteristics in the general population.
